Harnessing Nanogold in Therapeutic Cancer Vaccines
ACS Nano Medicine · 14.11.2026
DOI: 10.1021/acsnanomed.6c00228 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano Medicine, online erschienen am 14.11.2026. Verfasst von Joshua Seaberg und 2 weiteren Autor:innen. Die Arbeit nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer immunotherapy offers potential to harness one’s own immune system to eliminate existing cancer cells. Within this therapeutic umbrella, therapeutic cancer vaccines (TCVs) have been designed to train lymphocytes to recognize cancer cells as foreign invaders and eliminate them from the body. To enact this training, scientists have employed nanoscale gold constructs (nanogold) in varying ways throughout the cyclical process of antigen uptake, dendritic cell maturation, antigen presentation, T cell migration, and cancer cell elimination. In this review, we highlight the use of nanogold in TCVs, emphasizing the distinct properties that have been harnessed to improve diverse aspects of the TCV cycle. Ultimately, we discuss the challenges of utilizing nanogold in TCVs and provide our perspective on the direction of the field in upcoming years.
Zitieren
APA
Seaberg, J., Bhattacharya, R., & Mukherjee, P. (2026). Harnessing Nanogold in Therapeutic Cancer Vaccines. ACS Nano Medicine. https://doi.org/10.1021/acsnanomed.6c00228
Vancouver
Seaberg J, Bhattacharya R, Mukherjee P. Harnessing Nanogold in Therapeutic Cancer Vaccines. ACS Nano Medicine. 2026. doi:10.1021/acsnanomed.6c00228
BibTeX
@article{Seaberg2026,
author = {Seaberg, Joshua and Bhattacharya, Resham and Mukherjee, Priyabrata},
title = {Harnessing Nanogold in Therapeutic Cancer Vaccines},
journal = {ACS Nano Medicine},
year = {2026},
doi = {10.1021/acsnanomed.6c00228}
}
EUVIMED